Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Jonathan W. Goldman
ResearcherPublications, citations & collaboration network
Jonathan W. Goldman is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 792 works, 35,087 citations, an h-index of 68 and an i10-index of 194.
792
Works
35,087
Citations
68
h-index
194
i10-index
How has Jonathan W. Goldman's publication output changed over time?
ScholarIQpublication output · 2015–2023
Output grew0% over the shown period — from 2 works in 2015 to 2 in 2023.
2
3
1
1
3
2
201520162017201920202023
What are the most-cited papers on Jonathan W. Goldman?
ScholarIQmost cited works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi
New England Journal of Medicine. 20156,267 CitationsOPEN ACCESS
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz
The Lancet. 20192,246 Citations
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
New England Journal of Medicine. 20201,780 CitationsOPEN ACCESS
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian, Aaron Lisberg, Krikor Bornazyan, Darlene Veruttipong, Jonathan W. Goldman, Silvia C. Formenti, Edward B. Garon, Percy Lee
The Lancet Oncology. 20171,094 Citations
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal Ready, David E. Gerber, Laura Q.M. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, William J. Geese, Shruti Agrawal, Tina C. Young, Xuemei Li, Scott Antonia
The Lancet Oncology. 2016964 CitationsOPEN ACCESS
Related on ScholarIQ
Santa Monica College
Institution
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Paper
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paper
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Paper
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Paper
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Paper